The cover for issue 61 of Oncotarget features Figure 4, ‘The influence of stress conditions on API-5 expression and inhibition,’ by Bousquet, et al.

IMAGE

Credit: Correspondence to – Melanie Di Benedetto – melanie.dibenedetto@univ-paris13.fr and Guilhem Bousquet – guilhem.bousquet@aphp.fr


The cover for issue 61 of Oncotarget features Figure 4, “The influence of stress conditions on API-5 expression and inhibition,” by Bousquet, et al.

78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

Further studies on API-5 expression and inhibition were performed on patient-derived TNBC xenografts, one highly sensitive to chemotherapies and the other resistant to most tested drugs.

Clinical analyses of the 78 TNBC biopsies revealed that API-5 was more markedly expressed in endothelial cells before any treatment among patients with chemoresistant TNBC, and this was associated with greater micro-vessel density.

Dr. Melanie Di Benedetto and Dr. Guilhem Bousquet said, “Apoptosis Inhibitor-5 (API-5) also called Anti-Apoptosis Clone 11 (AAC-11) is a 58-kDa nuclear protein highly conserved across species.

API-5 was originally identified as an anti-apoptotic protein in mouse fibroblasts and in human cervical carcinoma cell lines, in which API-5 significantly enhanced cell survival after serum deprivation or ultraviolet sensitization.

In vitro, a decrease in API-5 expression sensitized human cancer cell lines to apoptosis, and increased their sensitivity to anticancer drugs.

In human osteocarcinoma cells, API-5 promotes survival through the inhibition of an E2 promoter-binding factor, and the integrity of the leucine zipper domain is required for the anti-apoptotic functions of API-5.

Previous authors engineered an anti-API5 peptide composed of the LZ domain fused with the Antennapedia/Penetrating protein domain since the integrity of this domain is essential for the function of API-5. This LZ peptide is able to penetrate cells in vitro, and to cancel the API-5/acinus interaction.

In this pre-clinical study, the authors studied the expression of API-5 in patients with chemotherapy-resistant TNBC and the inhibition of API-5 in a resistant TNBC xenograft model.

The Benedetto/Bousquet Research Team concluded that Hypoxia is associated with drug resistance and they have previously demonstrated a link between cancer stem-cells, hypoxic niches and resistance to sunitinib in renal cell carcinoma.

In vivo, hypoxia has been shown to induce resistance to apoptosis in human cervical cancer cell lines through a selection of p53-mutated cells.

Full text – https://doi.org/10.18632/oncotarget.27312

Correspondence to – Melanie Di Benedetto – melanie.dibenedetto@univ-paris13.fr and Guilhem Bousquet – guilhem.bousquet@aphp.fr

Keywords
triple-negative breast cancer,
chemotherapy resistance,
apoptosis-inhibitor-5,
peptide,
anti-angiogenic therapy

Media Contact
@RYANJAMESJESSUP
MEDIA@IMPACTJOURNALS.COM
800-922-0957 x105

Original Source

http://www.oncotarget.com/news/pr/high-expression-of-apoptosis-protein-api-5-in-chemoresistant-triple-negative-breast-cancers-an-innovative-target

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27312

Source